<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Performance Evaluation on FinanClub</title>
    <link>https://finan.club/tags/performance-evaluation/</link>
    <description>Recent content in Performance Evaluation on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Aug 2023 06:45:43 +0000</lastBuildDate><atom:link href="https://finan.club/tags/performance-evaluation/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title> BSX</title>
      <link>https://finan.club/us/bsx/</link>
      <pubDate>Tue, 08 Aug 2023 06:45:43 +0000</pubDate>
      
      <guid>https://finan.club/us/bsx/</guid>
      <description>score:957
Chances: Boston Scientific&amp;rsquo;s Q2 earnings saw organic and operational revenue growth in core business segments and geographies. Continued strength in BD&amp;rsquo;s Life Sciences segment&amp;rsquo;s base business is expected to benefit Q3 sales. Boston Scientific stock rose as hospital procedures stabilized after the Covid pandemic, contributing to a 20% rise in earnings.</description>
    </item>
    
  </channel>
</rss>
